首页/数据集/Dataset from A Randomised, Double-blind, Placebo Controlled, Parallel Group, Dose Ranging Study Evaluating the Efficacy and Safety of GW642444M Administered Once Daily Compared With Placebo for 28 Days in Adolescent and Adult Subjects With Persistent Asthma

Dataset from A Randomised, Double-blind, Placebo Controlled, Parallel Group, Dose Ranging Study Evaluating the Efficacy and Safety of GW642444M Administered Once Daily Compared With Placebo for 28 Days in Adolescent and Adult Subjects With Persistent Asthma

NIAID Data Ecosystem2026-05-02 收录

哮喘药物临床试验

哮喘治疗疗效评估

数据链接：

https://doi.org/10.25934/00000585 数据链接链接失效反馈

官方服务：

资源简介：

This study is designed to determine if the investigational drug is effective and safe in individuals with asthma

应用场景：

创建时间：

2024-11-26

急性重症哮喘急诊治疗

哮喘药物临床试验

Additional file 5.

NIAID Data Ecosystem70

Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Study

哮喘药物临床试验

长效支气管扩张剂安全性

BackgroundThis study assessed the long-term safety and efficacy of tiotropium Respimat, a long-acting inhaled anticholinergic bronchodilator, in asthma, added on to inhaled corticosteroids (ICS) with

Figshare2016-01-15 更新20

Dataset from A Multi-center, Randomized, 12-week Treatment, Doubleblind Study to Assess the Efficacy and Safety of QMF149 (150/80 Microgram) Compared With MF Twisthaler® (200 Microgram) in Adult and Adolescent Patients With Asthma

哮喘药物临床试验

呼吸系统疾病治疗

The purpose of the trial was to evaluate efficacy and safety of QMF149 150/80 microgram o.d.delivered via Concept1 compared to MF 200 microgram o.d., delivered via Twisthaler® in terms of lung functio

NIAID Data Ecosystem10

A Multicentre, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase III Efficacy and Safety Study of Benralizumab (MEDI-563) Added to High-dose Inhaled Corticosteroid Plus Long-acting β2 Agonist in Patients With Uncontrolled Asthma

哮喘药物临床试验

呼吸系统疾病疗效评估

The purpose of this study is to determine whether Benralizumab reduces the number of asthma exacerbations in patients who remain uncontrolled on high doses of ICS-LABA.

DataCite Commons2025-05-01 更新20

Dataset from A Randomized, Double-Blind, Parallel Group, Multicenter Study of Fluticasone Furoate/Vilanterol 200/25 mcg Inhalation Powder, Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder, and Fluticasone Furoate 100 mcg Inhalation Powder in the Treatment of Persistent Asthma in Adults and Adolescents

哮喘药物临床试验

吸入制剂疗效评估

This is a Phase III, multicenter, randomized, double-blind, stratified, parallel-group study with three active comparators in subjects with moderate to severe persistent asthma. The study consists of

NIAID Data Ecosystem20

Dataset from A Randomised, Double-blind, Placebo Controlled, Parallel Group, Dose Ranging Study Evaluating the Efficacy and Safety of GW642444M Administered Once Daily Compared With Placebo for 28 Days in Adolescent and Adult Subjects With Persistent Asthma

资源简介：

相关数据集